Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Tarceva

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Tarceva was produced by Roche and Astellas.

AZ sets price of new lung cancer drug Tagrisso

AZ sets price of new lung cancer drug Tagrisso The drug is a third-generation EGFR inhibitor, which is designed to overcome resistance to other drugs in the class such as Roche/Astellas' $2bn-a-year Tarceva (erlotinib), AZ's

Astellas sells dermatology unit to Leo for €675m

Astellas sells dermatology unit to Leo for €675m The overarching aim is to prepare for the forthcoming patent expiries on big-selling drugs Vesicare (solifenacin succinate) for overactive bladder and cancer therapy Tarceva (erlotinib).

Boehringer takes third-generation NSCLC drug into pivotal trials

Boehringer takes third-generation NSCLC drug into pivotal trials Tarceva (erlotinib) and AstraZeneca's Iressa (gefitinib), as well as Boehringer's own second-generation drug Giotrif (afatinib).

Oncology directions

Oncology directions Most of the drugs in lung cancer score four, but Roche's lung cancer drug Tarceva (erlotinib) scored just one.

Iressa set for US market return after FDA approval

Iressa set for US market return after FDA approval other first-generation EGFR inhibitors such as Roche/OSI's Tarceva (erlotinib) as well as newer drugs such as Boehringer Ingelheim's Giotrif (afatinib).

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics